Health Canada has accepted a new drug submission for a novel oral painkiller that could offer millions of Canadians an alternative to opioids and NSAIDs for the first time in more than two decades. The medication, suzetrigine, is a selective pain signal inhibitor designed to treat moderate-to-severe acute pain in adults without acting on the brain’s reward centers.
Each year, approximately 8 million Canadian adults are prescribed medication for acute pain, often relying on opioids or nonsteroidal anti-inflammatory drugs. Suzetrigine works by blocking the NaV1.8 sodium channel, a protein found only on peripheral pain-sensing neurons. Because this channel is not expressed in the brain, the drug is not associated with addiction, offering a fundamentally different approach to pain relief. The submission is based on data from three Phase 3 and two Phase 2 studies, which showed a favorable benefit-to-risk profile in patients with postoperative and other acute pain.
If approved, suzetrigine would be the first new class of acute pain medicine in Canada in more than 20 years. The U.S. Food and Drug Administration already approved the drug under the brand name JOURNAVX in January 2025, after granting it breakthrough therapy, fast track, and priority review designations. Vertex Pharmaceuticals has requested an aligned review with Canadian health technology assessment agencies, including Canada’s Drug Agency and Quebec’s INESSS, to help speed patient access if the drug is cleared.
The regulatory review marks a hopeful step for patients and clinicians seeking safer options for short-term pain. Vertex has stated it aims to address a significant unmet need, and the aligned review process is designed to coordinate decisions between Health Canada and reimbursement bodies. Canadians and their doctors may soon have a new tool to manage acute pain without the risks tied to older drug classes.